MG Biomed
Advanced solutions for detecting and reversing frailty in the elderly using AI and personalized analysis.
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
| Total Funding | 000k | ||
MG Biomed S.L. is at the forefront of addressing frailty in the elderly through its FrailStop project. This initiative leverages advanced technology, including sensors, data tracking, and Artificial Intelligence, to assess, treat, and monitor frailty. By providing healthcare professionals and older adults with critical information, the company enables proactive measures to prevent and even reverse frailty. Operating in the healthcare sector, MG Biomed serves both medical professionals and the elderly population. The business model revolves around offering technological solutions that integrate seamlessly into healthcare practices, generating revenue through partnerships and service contracts. Since its inception, MG Biomed has been involved in numerous competitive projects, securing significant research funding. The company is also engaged in educational and social initiatives, contributing to the broader community. Keywords: frailty, elderly, healthcare, AI, sensors, data tracking, prevention, treatment, monitoring, personalized analysis.